TNXP
Tonix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Stock Price Surged Significantly
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TNXP
Tonix Pharmaceuticals Holding Corp.
A clinical-stage biopharmaceutical company focused on therapeutics to treat and prevent human disease and alleviate suffering
26 Main Street, Suite 101, Chatham, New Jersey 07928
--
Tonix Pharmaceuticals Holding Corp was founded in Nevada on November 16, 2007. The company is a clinical-stage biopharmaceutical company focused on the development of therapies and vaccines to treat and prevent human diseases and reduce suffering. The company has a large number of products under development, which are curated through in-house discovery, licensing, acquisitions, and collaborations with academic institutions and contract research organizations. The company continues to build capabilities in synthetic biology, precision medicine, protein engineering, medicinal chemistry, molecular biology, pharmacogenomics and clinical-scale manufacturing. The therapies the company is developing include small molecules and biological agents.
Company Financials
EPS
TNXP has released its 2025 Q3 earnings. EPS was reported at -3.59, versus the expected -2.75, missing expectations. The chart below visualizes how TNXP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TNXP has released its 2025 Q3 earnings report, with revenue of 3.29M, reflecting a YoY change of 16.58%, and net profit of -32.01M, showing a YoY change of -125.22%. The Sankey diagram below clearly presents TNXP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
